We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

80 hedge funds and large institutions have $39.7M invested in Cue Biopharma in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 20 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

632% more call options, than puts

Call options by funds: $769K | Put options by funds: $105K

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

25% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 20

24% more capital invested

Capital invested by funds: $32.1M → $39.7M (+$7.59M)

7% more funds holding

Funds holding: 75 → 80 (+5)

0.07% more ownership

Funds ownership: 1.04% → 1.11% (+0.07%)

Holders
80
Holders Change
+5
Holders Change %
+6.67%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
25
Reduced
20
Closed
6
Calls
$769K
Puts
$105K
Net Calls
+$664K
Net Calls Change
+$522K

Top Buyers

Rank Fund Capital Flow
1
BL
Bleichroeder LP
New York
+$2.38M
2
BlackRock
BlackRock
New York
+$500K
3
Morgan Stanley
Morgan Stanley
New York
+$488K
4
Bank of America
Bank of America
North Carolina
+$185K
5
Jane Street
Jane Street
New York
+$130K

Top Sellers

Rank Fund Capital Flow
1
SMH
Sanders Morris Harris
Texas
-$713K
2
SPC
Sigma Planning Corp
Michigan
-$324K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$259K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$140K
5
Wells Fargo
Wells Fargo
California
-$116K
Name Holding Trade Value Shares
Change 		Change in
Stake
SPC
1
Slate Path Capital
New York
$6.34M – – –
BlackRock
2
BlackRock
New York
$6.17M +$500K +6,994 +10%
Vanguard Group
3
Vanguard Group
Pennsylvania
$5.63M +$19.1K +267 +0.4%
BL
4
Bleichroeder LP
New York
$4.63M +$2.38M +33,333 +132%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$2.15M +$121K +1,696 +7%
State Street
6
State Street
Massachusetts
$1.8M -$34.5K -483 -2%
RSWM
7
Robertson Stephens Wealth Management
California
$1.26M – – –
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$1.21M -$259K -3,621 -19%
Northern Trust
9
Northern Trust
Illinois
$1.01M +$126K +1,756 +16%
MAM
10
Monaco Asset Management
Monaco
$904K -$41.7K -583 -5%
Morgan Stanley
11
Morgan Stanley
New York
$870K +$488K +6,829 +165%
Millennium Management
12
Millennium Management
New York
$728K -$91.4K -1,278 -12%
Bank of America
13
Bank of America
North Carolina
$703K +$185K +2,585 +41%
AR
14
Advisory Research
Illinois
$679K – – –
Stifel Financial
15
Stifel Financial
Missouri
$512K +$111K +1,559 +32%
N
16
Nuveen
North Carolina
$506K – – –
CC
17
Carlson Capital
Texas
$317K -$35.7K -500 -11%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$289K +$15.1K +211 +6%
SPC
19
Sigma Planning Corp
Michigan
$287K -$324K -4,528 -56%
Charles Schwab
20
Charles Schwab
California
$279K +$22.9K +320 +10%
GLA
21
Good Life Advisors
Pennsylvania
$264K -$28.6K -400 -11%
UBS Group
22
UBS Group
Switzerland
$262K +$48K +671 +25%
Renaissance Technologies
23
Renaissance Technologies
New York
$230K +$65.3K +914 +46%
HighTower Advisors
24
HighTower Advisors
Illinois
$206K – – –
AC
25
Annandale Capital
Texas
$172K – – –
1
2 3 4

CUE Hedge Fund Activity: Q4 2023 in Review

80 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2023, worth a combined $39.7M — up 24% from $32.1M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CUE positions and 6 closed out — a net gain of 5 holders — while 25 added to existing stakes and 20 trimmed.

The largest buyer was Bleichroeder LP, adding an estimated $2.38M. The largest seller was Sanders Morris Harris, exiting entirely with an estimated $713K sold.

  • 80 institutional investors held Cue Biopharma (CUE) as of Q4 2023, up from 75 in Q3 2023.
  • Funds reported $39.7M of Cue Biopharma stock for Q4 2023, up 24% quarter-over-quarter.
  • 11 funds opened new Cue Biopharma positions in Q4 2023 and 6 closed out, a net change of +5 holders.
  • The largest Cue Biopharma buyer in Q4 2023 was Bleichroeder LP, an estimated $2.38M added.
  • The largest Cue Biopharma seller in Q4 2023 was Sanders Morris Harris, an estimated $713K sold.

Based on aggregated 13F filings for Q4 2023.